Skip to main content

VORANIGO

Generic: vorasidenib

Data may be stale·Apr 23, 2026
Manufacturer
Servier
NDC
72694-728
RxCUI
2690653
Route
ORAL
ICD-10 indication
I25.2

Affordability Check

How much will you actually pay for VORANIGO?

In 30 seconds, see every legitimate way to afford VORANIGO — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About VORANIGO

What is this medication? Voranigo is a prescription medication used to treat adults and children twelve years of age and older who have been diagnosed with specific types of brain cancer called Grade 2 astrocytoma or oligodendroglioma. This treatment is specifically for tumors that carry mutations in the IDH1 or IDH2 genes. It is typically administered after the patient has undergone a surgical procedure, such as a biopsy or tumor resection, to help control the growth of the cancer.

The medication functions as a targeted inhibitor that blocks the activity of the mutated IDH1 and IDH2 enzymes. By doing so, Voranigo reduces the buildup of harmful metabolites that drive tumor progression, which can help delay the need for more aggressive treatments like chemotherapy or radiation. It is the first oral targeted therapy approved for patients with these specific low-grade gliomas.

Copay & patient assistance

  • Patient Copay Amount: As little as $0 per prescription
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Must be a resident of the U.S. or Puerto Rico; must have commercial or private insurance; patients with government-funded insurance (including Medicare, Medicaid, Medigap, Department of Defense, Veterans Affairs, or TRICARE) are not eligible.
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How VORANIGO appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

75%

4,136 of 5,499 plans

Most common tier

Tier 5

On 79% of covering formularies

Prior authorization required

99%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)59
18%
Tier 2 (generic)2
1%
Tier 4 (non-preferred brand)7
2%
Tier 5 (specialty)259
79%
Tier 61
0%

Step therapy: 0% of formularies

Quantity limits: 68% of formularies

Coverage breadth: 328 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.